The stock has a 36-month beta value of 0.91. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CVKD is 1.33M, and at present, short sellers hold a 1.48% of that float. On July 01, 2025, the average trading volume of CVKD was 21.98K shares.
CVKD) stock’s latest price update
Cadrenal Therapeutics Inc (NASDAQ: CVKD)’s stock price has increased by 15.42 compared to its previous closing price of 10.44. However, the company has seen a 5.33% increase in its stock price over the last five trading sessions. businesswire.com reported 2025-05-15 that PONTE VEDRA, Fla.–(BUSINESS WIRE)—- $CVKD #ESKD–Cadrenal announces manufacturing and supply chain milestones for its lead drug, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant.
CVKD’s Market Performance
Cadrenal Therapeutics Inc (CVKD) has seen a 5.33% rise in stock performance for the week, with a -9.84% decline in the past month and a -34.72% plunge in the past quarter. The volatility ratio for the week is 11.75%, and the volatility levels for the past 30 days are at 7.92% for CVKD. The simple moving average for the last 20 days is -8.94% for CVKD stock, with a simple moving average of -22.62% for the last 200 days.
Analysts’ Opinion of CVKD
Many brokerage firms have already submitted their reports for CVKD stocks, with Noble Capital Markets repeating the rating for CVKD by listing it as a “Outperform.” The predicted price for CVKD in the upcoming period, according to Noble Capital Markets is $4 based on the research report published on December 18, 2023 of the previous year 2023.
CVKD Trading at -17.59% from the 50-Day Moving Average
After a stumble in the market that brought CVKD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.38% of loss for the given period.
Stock Fundamentals for CVKD
The total capital return value is set at -2.15. Equity return is now at value -208.59, with -171.09 for asset returns.
Currently, EBITDA for the company is -10.65 million with net debt to EBITDA at 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.31.
Conclusion
To sum up, Cadrenal Therapeutics Inc (CVKD) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
